|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. June 17–2010.(Epub ahead of
print).
|
|
2
|
Murad AM, Santiago FF, Petroianu A, Rocha
PR, Rodrigues MA and Rausch M: Modified therapy with
5-fluorouracil, doxorubicin, and methotrexate in advanced gastric
cancer. Cancer. 72:37–41. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pyrhönen S, Kuitunen T, Nyandoto P and
Kouri M: Randomised comparison of fluorouracil, epidoxorubicin and
methotrexate (FEMTX) plus supportive care with supportive care
alone in patients with non-resectable gastric cancer. Br J Cancer.
71:587–591. 1995.PubMed/NCBI
|
|
4
|
Wagner AD, Grothe W, Haerting J, Kleber G,
Grothey A and Fleig WE: Chemotherapy in advanced gastric cancer: a
systematic review and meta-analysis based on aggregate data. J Clin
Oncol. 24:2903–2909. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vanhoefer U, Rougier P, Wilke H, et al:
Final results of a randomized phase III trial of sequential
high-dose methotrexate, fluorouracil, and doxorubicin versus
etoposide, leucovorin, and fluorouracil versus infusional
fluorouracil and cisplatin in advanced gastric cancer: A trial of
the European Organization for Research and Treatment of Cancer
Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol.
18:2648–2657. 2000.
|
|
6
|
Van Cutsem E, Moiseyenko VM, Tjulandin S,
et al: Phase III study of docetaxel and cisplatin plus fluorouracil
compared with cisplatin and fluorouracil as first-line therapy for
advanced gastric cancer: a report of the V325 Study Group. J Clin
Oncol. 24:4991–4997. 2006.PubMed/NCBI
|
|
7
|
Cunningham D, Starling N, Rao S, et al;
Upper Gastrointestinal Clinical Studies Group of the National
Cancer Research Institute of the United Kingdom. Capecitabine and
oxaliplatin for advanced esophagogastric cancer. N Engl J Med.
358:36–46. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Koizumi W, Narahara H, Hara T, et al: S-1
plus cisplatin versus S-1 alone for first-line treatment of
advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet
Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Boku N, Yamamoto S, Fukuda H, et al:
Fluorouracil versus combination of irinotecan plus cisplatin versus
S-1 in metastatic gastric cancer: a randomised phase 3 study.
Lancet Oncol. 10:1063–1069. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ajani JA, Rodriguez W, Bodoky G, et al:
Multicenter phase III comparison of cisplatin/S-1 with
cisplatin/infusional fluorouracil in advanced gastric or
gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin
Oncol. 28:1547–1553. 2010. View Article : Google Scholar
|
|
11
|
Thuss-Patience PC, Kretzschmar A, Deist T,
et al: Irinotecan versus best supportive care (BSC) as second-line
therapy in gastric cancer. A randomized phase III study of the
Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol.
27(Suppl 15): abs. 4540. 2009.PubMed/NCBI
|
|
12
|
Hironaka S, Zenda S, Boku N, Fukutomi A,
Yoshino T and Onozawa Y: Weekly paclitaxel as second-line
chemotherapy for advanced or recurrent gastric cancer. Gastric
Cancer. 9:14–18. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kodera Y, Ito S, Mochizuki Y, et al: A
phase II study of weekly paclitaxel as second-line chemotherapy for
advanced gastric Cancer (CCOG0302 study). Anticancer Res.
27:2667–2671. 2007.PubMed/NCBI
|
|
14
|
Yamada Y, Shirao K, Ohtsu A, et al: Phase
II trial of paclitaxel by three-hour infusion for advanced gastric
cancer with short premedication for prophylaxis against
paclitaxel-associated hypersensitivity reactions. Ann Oncol.
12:1133–1137. 2001. View Article : Google Scholar
|
|
15
|
Yamaguchi K, Tada M, Horikoshi N, et al:
Phase II study of paclitaxel with 3-h infusion in patients with
advanced gastric cancer. Gastric Cancer. 5:90–95. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wesolowski R, Lee C and Kim R: Is there a
role for second-line chemotherapy in advanced gastric cancer?
(Review). Lancet Oncol. 10:903–912. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Grothey A, Sargent D, Goldberg RM and
Schmoll HJ: Survival of patients with advanced colorectal cancer
improves with the availability of fluorouracil-leucovorin,
irinotecan, and oxaliplatin in the course of treatment. J Clin
Oncol. 22:1209–1214. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rosenberg P, Andersson H, Boman K, et al:
Randomized trial of single agent paclitaxel given weekly versus
every three weeks and with peroral versus intravenous steroid
premedication to patients with ovarian cancer previously treated
with platinum. Acta Oncol. 41:418–424. 2002. View Article : Google Scholar
|
|
19
|
Sparano JA, Wang M, Martino S, et al:
Weekly paclitaxel in the adjuvant treatment of breast cancer. N
Engl J Med. 358:1663–1671. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shimoyama R, Yasui H, Boku N, et al:
Weekly paclitaxel for heavily treated advanced or recurrent gastric
cancer refractory to fluorouracil, irinotecan, and cisplatin.
Gastric Cancer. 12:206–211. 2009. View Article : Google Scholar : PubMed/NCBI
|
